Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Neurology & CNS R&D Pipeline

Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Programs 675

Quick answer

Neurology & CNS: NovaPharmaNews indexes 675 neurology & cns clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Top sponsors

Pipeline programs

Page 12 of 15

  1. NIO752B12201

    Novartis Pharmaceuticals

    Alzheimer’s Disease

    phase 1 other active

    1 trial

  2. NMRA-323511

    Neumora Therapeutics

    Alzheimer's Disease

    phase 1 small molecule completed

    1 trial

  3. NXPTEGO/23/P1-4

    NEURAXPHARM AUSTRALIA PTY LIMITED

    Multiple Sclerosis

    phase 1 other active

    1 trial

  4. Narcan 40 MG/ML Nasal Spray

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Induced Respiratory Depression

    phase 1 small molecule active

    1 trial

  5. ONC206 Powder

    AXIM BIOTECHNOLOGIES, INC.

    Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors

    phase 1 small molecule active

    1 trial

  6. Obecabtagene autoleucel (obe-cel)

    Autolus GmbH

    Progressive Multiple Sclerosis

    phase 1 mab active

    1 trial

  7. Olanzapine Extended Release

    Teva Pharma GmbH

    Schizophrenia, Schizoaffective Disorder

    phase 1 small molecule completed

    1 trial

  8. Opicapone

    NEUROCRINE BIOSCIENCES INC

    Parkinson Disease

    phase 1 small molecule completed

    1 trial

  9. Oxcarbazepine (brand name vs generic drugs)

    BRIGHT MINDS BIOSCIENCES INC.

    Epilepsy

    phase 1 small molecule completed

    1 trial

  10. PIPE-307

    Contineum Therapeutics

    Multiple Sclerosis

    phase 1 small molecule completed

    2 trials

  11. PIPE-791

    Contineum Therapeutics

    Multiple Sclerosis

    phase 1 small molecule completed

    1 trial

  12. PRAX-628-102

    Chongqing Precision Biotech Co., Ltd

    Epilepsy

    phase 1 other active

    1 trial

  13. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Parkinson Disease

    phase 1 small molecule terminated

    1 trial

  14. Placebo

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 1 small molecule completed

    1 trial

  15. Pramipexole

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 1 small molecule completed

    1 trial

  16. RAP-219-103

    Rapport Therapeutics

    Epilepsy

    phase 1 other active

    1 trial

  17. Risperidone

    The First People's Hospital of Lianyungang

    Schizophrenia

    phase 1 small molecule active

    1 trial

  18. Roflumilast

    Takeda

    Schizophrenia

    phase 1 small molecule completed

    1 trial

  19. SAM-315

    Wyeth is now a wholly owned subsidiary of Pfizer

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  20. SER-214

    Serina Therapeutics

    Parkinson's Disease

    phase 1 small molecule active

    1 trial

  21. SER-252 (PEOZ-apomorphine)

    Serina Therapeutics

    PARKINSON DISEASE (Disorder)

    phase 1 small molecule active

    1 trial

  22. SPD489 (Lisdexamfetamine dimesylate)

    Takeda

    Schizophrenia

    phase 1 small molecule completed

    1 trial

  23. SPN-804O

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsies, Partial

    phase 1 small molecule completed

    1 trial

  24. Safety for A Phase 1, Randomized, Double-B…

    Lacuna Pharma Pty Ltd

    A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses and Food Effect of Leucettinib-21 in Healthy Male Subjects, followed by an open single dose of Leucettinib-21 in Down Syndrome individuals, and patients with Alzheimer’s disease

    phase 1 other active

    1 trial

  25. Stem Cell

    EuroGen Pharmaceuticals Ltd

    Neurological; Disorder, Nervous System

    phase 1 mab terminated

    1 trial

  26. TAK-058

    Takeda

    Schizophrenia

    phase 1 small molecule terminated

    1 trial

  27. TAK-063

    Takeda

    Schizophrenia

    phase 1 small molecule completed

    1 trial

  28. TAK-071

    Takeda

    Alzheimer Disease

    phase 1 small molecule terminated

    1 trial

  29. TAK-831 Oral Suspension

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia, Cerebellar Ataxia

    phase 1 small molecule terminated

    1 trial

  30. TAK-935

    Takeda

    Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents

    phase 1 small molecule completed

    1 trial

  31. TG1101-RMS-SC101

    TG THERAPEUTICS, INC.

    Relapsing multiple sclerosis, Myasthenia Gravis

    phase 1 small molecule active

    1 trial

  32. TTP4000

    vTv Therapeutics

    Alzheimer's Disease

    phase 1 small molecule completed

    1 trial

  33. TV44749-BA-10196

    Lacuna Pharma Pty Ltd

    Schizophrenia

    phase 1 other active

    1 trial

  34. Topiramate IR

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsy

    phase 1 small molecule completed

    1 trial

  35. UB-312

    BRIGHT MINDS BIOSCIENCES INC.

    Parkinson's Disease

    phase 1 mab completed

    1 trial

  36. UECHUP-DON/23-5

    Laboratorios Tillomed Spain S.L.U

    Alzheimer's disease

    phase 1 other active

    1 trial

  37. UECHUP-MEM/25-6

    Laboratorios Tillomed Spain S.L.U

    Alzheimer’s disease

    phase 1 other active

    1 trial

  38. UECHUP-RAS/24-2

    Laboratorios Tillomed Spain S.L.U

    Parkinson´s disease

    phase 1 other active

    1 trial

  39. UX-GIP001

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Epilepsy

    phase 1 small molecule active

    1 trial

  40. VHX-896 and iloperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Schizophrenia

    phase 1 small molecule completed

    1 trial

  41. VX15/2503

    VACCINEX, INC.

    Multiple Sclerosis

    phase 1 small molecule completed

    1 trial

  42. VY-AADC01

    NEUROCRINE BIOSCIENCES INC

    Parkinson's Disease

    phase 1 mab completed

    1 trial

  43. VY-AADC01

    NEUROCRINE BIOSCIENCES INC

    Idiopathic Parkinson's Disease

    phase 1 small molecule completed

    1 trial

  44. VY-AADC02

    NEUROCRINE BIOSCIENCES INC

    Parkinson's Disease

    phase 1 mab completed

    1 trial

  45. Vagus Nerve Stimulation

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Refractory Epilepsy

    phase 1 other active

    1 trial

  46. Velusetrag

    Theravance Biopharma Ireland Umited

    Alzheimer's Disease

    phase 1 small molecule completed

    1 trial

  47. WN45319

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  48. [123I] IBVM and SPECT imaging

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many neurology & cns pipeline programs are tracked?

675 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.